Research Progress on the Role of Atorvastatin in the Treatment of Coronary Heart Disease

  • Shupeng Jiang Gannan Medical University
DOI: https://doi.org/10.18686/aem.v11i4.345
Keywords: Atorvastatin, Coronary Heart Disease, Treatment

Abstract

The basic pathological change of coronary heart disease is atherosclerosis, and the main risk factor is abnormal lipid metabolism. Atorvastatin is the most commonly used lipid-lowering drug. This paper mainly describes the research progress of atorvastatin in terms of pharmacological effects, dosing and deficiencies.

References

[1] Bai X, Zhang JJ. Application value of comprehensive nursing intervention in patients with complete coronary occlusion after intervention [J] Journal of Cardiovascular Rehabilitation Medicine, 2021 (02): 207-211.

[2] Zhao P, Tao J, Yuan XC, Wu Y, Du L, Hu F. Efficacy and safety of long-term high-dose atorvastatin therapy after PCI in patients with coronary artery disease[J]. Journal of Clinical Cardiovascular Disease, 2017, 33(3): 226-230.

[3] Zhang JL. Comparison of clinical effects of Rosuvastatin and Atorvastatin in the treatment of coronary artery disease[J]. Journal of Clinical Rational Drug Use.

[4] Luo CF, Zhou M, He XR, Liu Y. Effect of atorvastatin on carotid atherosclerotic plaques in patients with coronary artery disease[J]. Modern Diagnosis and Therapy, 2019, 30(9): 1011- 8174(2019)09-1433-02.

[5] Tan WJ, Liu SH, Gao W, Liu L, Yuan H, Luo EL. Effect of atorvastatin calcium tablets on small and dense low-density lipoprotein cholesterol levels in patients with coronary artery disease[J]. Chinese Journal of Clinical Pharmacology, 2019, 36(2): 103-106.

[6] Zhang CR, Dai FL. Effects of atorvastatin combined with trimetazidine therapy on cardiac function and endothelial function in patients with coronary artery disease[J]. Journal of Pharmaceutical Forum, 2022, 43(12):83-86.

[7] Yang J, Xu B, Feng W, Ye SQ, Zhong HY. Efficacy of atorvastatin combined with trimetazidine in the treatment of coronary artery disease and its effect on vascular endothelial function[J]. Chinese Journal of Clinical Health Care, 2019, 22(3):383-385.

[8] Liu SG, Qi YJ, Wang SJ, Jin N, Li WG. Effects of intensive atorvastatin treatment on TNF-É‘, hs-CRP, and Hcy levels in patients with chronic heart failure in coronary heart disease[J]. Journal of Integrated Cardiovascular and Cerebrovascular Diseases in Chinese and Western Medicine, 2019, 17(1):96-98.

[9] Zhang LF. Effectiveness and safety analysis of different doses of atorvastatin in the treatment of coronary heart disease in the elderly[J]. Chinese Modern Physicians, 2022, 60(7):102-105.

[10] Mu M. Effectiveness of different doses of atorvastatin in the treatment of coronary heart disease in the elderly[J]. Chinese Community Physicians, 2022, 38(9):36-38.

[11] Liu SN, Tian XF, Wang Z, Xu M. Effects of different varieties of statins on glucose metabolism in non-diabetic patients with atherosclerotic coronary heart disease[J]. Chinese Medicine, 2019, 14(2):192-194.

[12] Wei GH, Zhang C, Zhu CJ, Wang XK. Analysis of the effect and safety of atorvastatin treatment in elderly patients with coronary heart disease with different nutritional status[J]. Sichuan Med., 2022, 43(3):253-256.
[13] Wang S. Exploring the anti-inflammatory effects of atorvastatin in the treatment of coronary heart disease (CHD)[J]. Contemporary Medicine., 2019, 25(6):100-102.

[14] Cao AH, Li G, Song WJ. Lipid regulation, anti-inflammatory and safety study of different doses of atorvastatin in patients with coronary intervention[J]. Hebei Med., 2017, 39(22): 3470-3472.

[15] Wang HL. Analysis of the clinical use value of low-dose atorvastatin in the treatment of chronic heart failure in elderly people with coronary heart disease[J]. Wisdom Health, 2022, 8(6):97-99.
Published
2023-03-02
Issue
Vol 11, No 4 (2022)
Section
Original Research Article

Copyright (c) 2023 Shupeng Jiang

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear

Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.